Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Precancerous Conditions 1Keratosis, Actinic 1Carcinoma, Squamous Cell 1

Interventions

Peripheral Blood Stem Cell Transplantation 9Cyclophosphamide 9Biopsy 8fludarabine phosphate 7Whole-Body Irradiation 6Tacrolimus 5Mycophenolic Acid 5Epoetin Alfa 5Colposcopy 5Celecoxib 5Busulfan 5Aminolevulinic Acid 5Sulindac 4Selenium 4Methotrexate 4Melphalan 4Cyclosporine 4Cetuximab 4Antilymphocyte Serum 4Polymerase Chain Reaction 3Imiquimod 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Gene Expression Profiling 3Etoposide 3Eflornithine 3Darbepoetin alfa 3Carboplatin 3Aspirin 3fludarabine 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Precancerous Conditions × Excipients × Clear all
NCT02844777 2023-01-12

Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis

Vidac Pharma

Phase 2 Completed
93 enrolled 13 charts
DermatologicOther neoplasm

Carcinoma, Squamous Cell, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡